Market revenue in 2023 | USD 1,327.4 million |
Market revenue in 2030 | USD 2,111.6 million |
Growth rate | 6.9% (CAGR from 2023 to 2030) |
Largest segment | Narcolepsy with cataplexy |
Fastest growing segment | Narcolepsy without Cataplexy |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, Secondary Narcolepsy |
Key market players worldwide | Teva Pharmaceutical Industries Ltd, Jazz Pharmaceuticals PLC, Harmony Biosciences Holdings Inc Ordinary Shares, Novartis AG ADR, Janssen Pharmaceuticals, Eli Lilly and Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to narcolepsy therapeutics market will help companies and investors design strategic landscapes.
Narcolepsy with cataplexy was the largest segment with a revenue share of 54.14% in 2023. Horizon Databook has segmented the North America narcolepsy therapeutics market based on narcolepsy with cataplexy, narcolepsy without cataplexy, secondary narcolepsy covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America narcolepsy therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into North America narcolepsy therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account